After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

A postgraduate medical student at the government hospital in Hassan district was allegedly assaulted in the early hours of ...

Zoom Communications reported solid fourth-quarter earnings but a weaker-than-expected outlook. Broad markets are steady while defense stocks rally after no feared scenarios, including far-right ...

UnitedHealth Group, Alphabet, Hims & Hers Health, Salesforce, and Johnson & Johnson are the five Healthcare stocks to watch today, according to MarketBeat’s stock screener tool. These companies had ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...

Hims & Hers reported a double beat in Q4, but faced an 18% stock drop after hours. Read why this drop is a good opportunity ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

Hims & Hers Health shares plunged in extended trading Monday after the online healthcare provider reported falling margins as costs rose.

The 'Fast Money' traders talk Hims & Hers shares falling despite beat as concerns around weight-loss business escalate.

Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...